Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahul Banerjee

Showing results (361-370 of 384) with videos related to

Pageof 39
Sort By:
Bone Marrow Transplantation|October 5, 2021
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysisOren Pasvolsky, Moshe Yeshurun, Raphael Fraser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T ConsortiumYucai Wang, Preetesh Jain, Frederick L Locke, et al.
Transplantation and Cellular Therapy|June 16, 2026
Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall SurvivalGurbakhash Kaur, Jennifer Logue, Ruta Brazauskas, et al.
Blood Advances|February 24, 2026
Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World AnalysisCarlyn Rose Tan, Saad Z Usmani, Andriy Derkach, et al.
American Journal of Hematology|March 21, 2026
The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent MyelomaMatthew J Rees, Raffaella Cassano Cassano, Melinda Tan, et al.
Transplantation and Cellular Therapy|June 27, 2026
Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR AnalysisKitsada Wudhikarn, Lohith Gowda, Qiran Ye, et al.
American Journal of Hematology|October 11, 2025
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-ResponseRahul Banerjee, Gurbakhash Kaur, Beatrice M Razzo, et al.
Leukemia|January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J Costa, Rahul Banerjee, Hira Mian, et al.
Blood Advances|December 3, 2024
Development and validation of predictive models of early immune effector cell-associated hematotoxicityEmily C Liang, Jennifer J Huang, Andrew J Portuguese, et al.
Journal of the American Chemical Society|July 21, 2020
High-Resolution XFEL Structure of the Soluble Methane Monooxygenase Hydroxylase Complex with its Regulatory Component at Ambient Temperature in Two Oxidation StatesVivek Srinivas, Rahul Banerjee, Hugo Lebrette, et al.
Pageof 39

Showing results (361-370 of 384) with videos related to

Sort By:
Pageof 39
Bone Marrow Transplantation|October 5, 2021
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysisOren Pasvolsky, Moshe Yeshurun, Raphael Fraser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T ConsortiumYucai Wang, Preetesh Jain, Frederick L Locke, et al.
Transplantation and Cellular Therapy|June 16, 2026
Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall SurvivalGurbakhash Kaur, Jennifer Logue, Ruta Brazauskas, et al.
Blood Advances|February 24, 2026
Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World AnalysisCarlyn Rose Tan, Saad Z Usmani, Andriy Derkach, et al.
American Journal of Hematology|March 21, 2026
The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent MyelomaMatthew J Rees, Raffaella Cassano Cassano, Melinda Tan, et al.
Transplantation and Cellular Therapy|June 27, 2026
Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR AnalysisKitsada Wudhikarn, Lohith Gowda, Qiran Ye, et al.
American Journal of Hematology|October 11, 2025
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-ResponseRahul Banerjee, Gurbakhash Kaur, Beatrice M Razzo, et al.
Leukemia|January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J Costa, Rahul Banerjee, Hira Mian, et al.
Blood Advances|December 3, 2024
Development and validation of predictive models of early immune effector cell-associated hematotoxicityEmily C Liang, Jennifer J Huang, Andrew J Portuguese, et al.
Journal of the American Chemical Society|July 21, 2020
High-Resolution XFEL Structure of the Soluble Methane Monooxygenase Hydroxylase Complex with its Regulatory Component at Ambient Temperature in Two Oxidation StatesVivek Srinivas, Rahul Banerjee, Hugo Lebrette, et al.
Pageof 39